• •Nature reports that biotechnology firms are shifting focus from traditional CRISPR DNA-cutting to epigenome editing, which modifies gene expression without altering the underlying genetic sequence.
• •Companies are leveraging CRISPR-based tools to 'silence' or 'activate' genes, aiming to treat chronic conditions while avoiding the risk of permanent, off-target DNA damage.
• •The transition remains in experimental phases, with critical questions remaining regarding the long-term durability of these chemical modifications and the risk of the body reversing the edits over time.

Biotech companies are transitioning from standard CRISPR gene editing to epigenetic editing, a method that alters gene expression rather than the genetic code itself. Unlike traditional CRISPR, which relies on making permanent double-strand breaks in DNA, these tools aim to toggle gene activity temporarily or semi-permanently. However, the scientific community remains cautious about the stability of these edits, as the biological mechanisms controlling epigenetic states are notoriously prone to drifting back to original settings. The success of these therapies will likely hinge on whether they can prove 'durable' results in human trials, a milestone that separates theoretical potential from clinical viability.